David P. Luci - 23 Feb 2024 Form 4 Insider Report for Acurx Pharmaceuticals, Inc. (ACXP)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Apr 2024, 21:56:33 UTC
Prior SEC filing
04 Jan 2024
Next SEC filing
08 Jan 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kostantinos Skordalos, Power of Attorney For: David P. Luci

Key filing fact

David P. Luci filed Form 4 for Acurx Pharmaceuticals, Inc. (ACXP) on 03 Apr 2024.

Key facts

  • This page summarizes David P. Luci's Form 4 filing for Acurx Pharmaceuticals, Inc. (ACXP).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 03 Apr 2024, 21:56.

Change

  • Previous filing in this sequence was filed on 04 Jan 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACXP transaction Derivative

Stock Option

Award

Transaction value
$0
Shares
+250,000
Change %
Price
$0.000000
Shares after
250,000
Date
23 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
250,000
Exercise price
$3.15
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On February 23, 2024 (the "Grant Date"), the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .